GlaxoSmithKline plc (ADR)  

(Public, NYSE:GSK)   Watch this stock  
Find more results for GSK
48.27
+0.07 (0.15%)
Real-time:   11:16AM EDT
NYSE real-time data - Disclaimer
Currency in USD
Range 48.22 - 48.58
52 week 48.08 - 56.73
Open 48.46
Vol / Avg. 1.97M/3.06M
Mkt cap 117.28B
P/E 14.62
Div/yield 0.65/5.50
EPS 3.30
Shares 4.86B
Beta 0.60
Inst. own 5%
Oct 22, 2014
Q3 2014 GlaxoSmithKline PLC Earnings Release - 7:00AM EDT - Add to calendar
Jul 23, 2014
Q2 2014 GlaxoSmithKline PLC Earnings Call
Jul 23, 2014
Q2 2014 GlaxoSmithKline PLC Earnings Release
Jun 2, 2014
GlaxoSmithKline at Jefferies Global Healthcare Conference
May 22, 2014
GlaxoSmithKline PLC United Way of Greater Philadelphia and Southern New Jersey Issue Call for Applications Totaling $400,000 in GSK IMPACT Awards Conference Call
May 22, 2014
GlaxoSmithKline PLC Triangle Community Foundation Issue Call for Applications Totaling $400,000 in GSK IMPACT Awards Conference Call
May 14, 2014
Pernix Therapeutics Holdings Inc Conference Call with GlaxoSmithKline to acquire the U.S rights to Treximet�
May 14, 2014
GlaxoSmithKline at Credit Suisse Stockholm Consumer and Healthcare IR Day
May 7, 2014
GlaxoSmithKline PLC Annual General Meeting
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin 12.62% 21.23%
Operating margin 20.45% 27.58%
EBITD margin - 34.46%
Return on average assets 7.17% 13.47%
Return on average equity 41.20% 84.96%
Employees 99,817 -
CDP Score - 98 A

Address

C8 Gsk House, 980 Great West R
BRENTFORD, ENG TW8 9GS
United Kingdom - Map
+44-20-80475000 (Phone)
+44-20-80477807 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

GlaxoSmithKline plc (GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. GSK�s principal pharmaceutical products include medicines in therapeutic areas: respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, antibacterials, oncology and emesis, dermatology, rare diseases, immuno-inflammation, vaccines and human immunodeficiency virus (HIV). The Company operates in three primary areas of business: Pharmaceuticals, Vaccines and Consumer Healthcare. On January 30, 2013, GSK acquired additional 29.3% interest in GlaxoSmithKline Consumer Healthcare Ltd. In May 2013, GlaxoSmithKline PLC acquired Okairos AG. In December 2013, Suntory Beverage & Food Ltd fully acquired Lucozade Ribena Suntory Limited from GlaxoSmithKline plc.

Officers and directors

Andrew Philip Witty Chief Executive Officer, Executive Director
Age: 49
Bio & Compensation  - Reuters
Simon Dingemans Chief Financial Officer, Executive Director
Age: 50
Bio & Compensation  - Reuters
Moncef Slaoui Chairman - Global Research & Development and Vaccines, Executive Director
Age: 54
Bio & Compensation  - Reuters
Deirdre P. Connelly President - North American Pharmaceuticals
Age: 53
Bio & Compensation  - Reuters
Roger Connor President - Global Manufacturing & Supply
Bio & Compensation  - Reuters
Shah Abbas Hussain President - Europe, Japan & EMAP
Age: 47
Bio & Compensation  - Reuters
Patrick Vallance President - Pharmaceuticals R&D
Bio & Compensation  - Reuters
Emma Walmsley President - Consumer Healthcare Worldwide
Bio & Compensation  - Reuters
Daniel Troy Senior Vice President, General Counsel
Bio & Compensation  - Reuters
Claire Thomas Senior Vice President - Human Resources
Bio & Compensation  - Reuters